<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0402256810
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZYTERO 25 mg Film Coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ALOGLIPTIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        105.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TAKEDA IRELAND LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TAKEDA IRELAND LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 651]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACEUTICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACETICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BH04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; ZYTERO is a prescription medicine used along with diet and exercise to improve blood sugar<br />(glucose) control in adults with type 2 diabetes.<br />&bull; ZYTERO is unlikely by itself to cause your blood sugar to be lowered to a dangerous level<br />(hypoglycemia). However, hypoglycemia may still occur with ZYTERO .<br />&bull; ZYTERO is not for people with type 1 diabetes.<br />&bull; ZYTERO is not for people with diabetic ketoacidosis (increased ketones in blood or urine).<br />It is not known if ZYTERO is safe and effective in children under the age of 18.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do NOT take Zytero :<br />&bull; if you are allergic to alogliptin or any of the other ingredients of this medicine (listed in<br />section 6)<br />&bull; if you have had a serious allergic reaction to any other similar medications that you take to<br />control your blood sugar. Symptoms of a serious allergic reaction may include; rash, raised<br />red patches on your skin (hives), swelling of the face, lips, tongue, and throat that may cause<br />difficulty in breathing or swallowing.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Zytero :<br />&bull; if you have type 1 diabetes (your body does not produce insulin)</p><p>&bull; if you have diabetic ketoacidosis (a complication of diabetes that occurs when the body is<br />unable to breakdown glucose because there is not enough insulin). Symptoms include<br />excessive thirst, frequent urination, loss of appetite, nausea or vomiting and rapid weight loss<br />&bull; if you are taking an anti-diabetic medicine known as sulphonylurea (e.g. glipizide,<br />tolbutamide, glibenclamide) or insulin. Your doctor may want to reduce your dose of<br />sulphonylurea or insulin when you take any of them together with Zytero in order to avoid too<br />low blood sugar (hypoglycaemia)<br />&bull; if you have kidney disease, you can still take this medicine but your doctor may reduce the<br />dose<br />&bull; if you have liver disease<br />&bull; if you suffer from heart failure<br />&bull; if you have had allergic reactions to any other medications that you take to control your blood<br />sugar. Symptoms may include general itching and feeling of heat especially affecting the<br />scalp, mouth, throat, palms of hands and soles of feet (Stevens-Johnson syndrome)<br />&bull; if you are taking insulin or an anti-diabetic medicine, your doctor may want to reduce your<br />dose of the other anti-diabetic medicine or insulin when you take either of them together with<br />Zytero in order to avoid low blood sugar<br />&bull; if you have or have had a disease of the pancreas<br />Children and adolescents<br />Zytero is not recommended for children and adolescents under 18 years due to the lack of data in<br />these patients.<br />Other medicines and Zytero<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask<br />your doctor or pharmacist for advice before taking this medicine.<br />There is no experience of using Zytero in pregnant women or during breast-feeding. Zytero should<br />not be used during pregnancy or breast-feeding unless your doctor thinks it is clearly necessary.</p><p>Driving and using machines<br />Zytero is not known to affect your ability to drive and use machines. Taking Zytero in combination<br />with medicines called sulphonylureas, insulin or combination therapy with thiazolidinedione plus<br />metformin can cause too low blood sugar levels (hypoglycaemia), which may affect your ability to<br />drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Take ZYTERO exactly as your doctor tells you to take it.<br />&bull; Take ZYTERO 1 time each day with or without food.<br />&bull; If you miss a dose, take it as soon as you remember. If you do not remember until it is time for<br />your next dose, skip the missed dose, and take the next dose at your regular time. Do not take<br />2 doses of ZYTERO at the same time<br />&bull; If you take too much ZYTERO , call your doctor or go to the nearest hospital emergency room<br />right away<br />&bull; If your body is under stress, such as from fever, infection, accident or surgery, the dose of<br />your diabetes medicines may need to be changed. Call your doctor right away</p><p>&bull; Stay on your diet and exercise programs and check your blood sugar as your doctor tells you<br />to<br />&bull; Your doctor may do certain blood tests before you start ZYTERO and during treatment as<br />needed. Your doctor may change your dose of ZYTERO based on the results of your blood<br />tests due to how well your kidneys are working<br />&bull; Your doctor will check your diabetes with regular blood tests, including your blood sugar<br />levels and your hemoglobin A1C<br />If you take more Zytero than you should<br />If you take more tablets than you should, or if someone else or a child takes your medicine, contact or<br />go to your nearest emergency centre straight away. Take this leaflet or some tablets with you so that<br />your doctor knows exactly what you have taken.<br />If you forget to take Zytero<br />If you forget to take a dose, take it as soon as you remember it. Do not take a double dose to make up<br />for a forgotten dose.<br />If you stop taking Zytero<br />Do not stop taking Zytero without consulting your doctor first. Your blood sugar levels may increase<br />when you stop taking Zytero .<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />STOP taking Zytero and contact a doctor immediately if you notice any of the following serious<br />side effects:<br />Not known (frequency cannot be estimated from the available data):<br />&bull; An allergic reaction. The symptoms may include: a rash, hives, swallowing or breathing<br />problems, swelling of your lips, face, throat or tongue and feeling faint.<br />&bull; A severe allergic reaction: skin lesions or spots on your skin that can progress to a sore<br />surrounded by pale or red rings, blistering and/or peeling of the skin possibly with symptoms<br />such as itching, fever, overall ill feeling, achy joints, vision problems, burning, painful or itchy<br />eyes and mouth sores (Stevens-Johnson syndrome and Erythema multiforme).<br />&bull; Severe and persistent pain in the abdomen (stomach area) which might reach through to your<br />back, as well as nausea and vomiting, as it could be a sign of an inflamed pancreas<br />(pancreatitis).<br />You should also discuss with your doctor if you experience the following side effects:<br />Common (may affect up to 1 in 10 people):<br />&bull; Symptoms of low blood sugar (hypoglycaemia) may occur when Zytero is taken in<br />combination with insulin or sulphonylureas (e.g. glipizide, tolbutamide, glibenclamide).<br />Symptoms may include: trembling, sweating, anxiety, blurred vision, tingling lips, paleness,<br />mood change or feeling confused. Your blood sugar could fall below the normal level, but can<br />be increased again by taking sugar. It is recommended that you carry some sugar lumps,<br />sweets, biscuits or sugary fruit juice.<br />&bull; Cold like symptoms such as sore throat, stuffy or blocked nose,<br />&bull; Rash<br />&bull; Itchy skin</p><p>&bull; Headache<br />&bull; Stomach ache<br />&bull; Diarrhoea<br />&bull; Indigestion, heartburn<br />Not known:<br />&bull; Liver problems such as nausea or vomiting, stomach pain, unusual or unexplained tiredness,<br />loss of appetite, dark urine or yellowing of your skin or the whites of your eyes.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects<br />not listed in this leaflet. You can also report side effects directly via the National Pharmacovigilance<br />and Drug Safety Centre (NPC) listed at the end of this leaflet. By reporting side effects you can help<br />provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30 &deg;C.<br />Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The<br />expiry date refers to the last day of that month.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Zytero contains<br />- The active substance is alogliptin benzoate.<br />Each 12.5 mg tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin<br />The other ingredients are: mannitol, microcrystalline cellulose, hydroxypropylcellulose,<br />croscarmellose sodium, magnesium stearate. In addition, the film-coating contains the following<br />inactive ingredients: hypromellose, titanium dioxide, ferric oxide (yellow) and polyethylene glycol<br />and is marked with gray F1 printing ink.<br />Each 25 mg tablet contains alogliptin benzoate equivalent to 25 mg alogliptin,<br />The other ingredients are: mannitol, microcrystalline cellulose, hydroxypropylcellulose,<br />croscarmellose sodium, magnesium stearate. In addition, the film-coating contains the following<br />inactive ingredients: hypromellose, titanium dioxide, ferric oxide (Red) and polyethylene glycol and is<br />marked with gray F1 printing ink.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ZYTERO tablets are available as film-coated tablets containing 12.5 mg or 25 mg of alogliptin as
follows:
ZYTERO 12.5 mg tablet: yellow, oval, biconvex, film-coated tablet with “TAK” and “ALG-12.5”
printed on one side
ZYTERO 25 mg tablet: light red, oval, biconvex, film-coated tablet with “TAK” and “ALG-25”
printed on one side
ZYTERO is available in a pack size of 28 tablets (4 blisters containing each 7 tablets).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder, secondary packaging and final release site:<br />Batterjee pharmaceutical factory<br />Industrial Area-phase-IV,<br />Jeddah-21443, Kingdom of Saudi<br />Manufacturing site:<br />Takeda Ireland Limited<br />Bray Business Park, Kilruddery, Bray<br />Co. Wicklow, Ireland<br />Primary Packaging site:<br />Packaging Coordinators, LLC<br />2200 Lake Shore Drive,<br />Woodstock, IL 60098, USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                January 2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&bull; زایتیرو ھي وصفة طبیة تُستخدم بمصاحبة الحمیة الغذائیة والتمارین الریاضیة لتحسین التحكم في مستوى السكر في الدم<br />. (الجلوكوز) للبالغین المصابین بداء السكري من النوع ۲<br />&bull; من المستبعد أن یسبب زایتیرو انخفاض مستوى السكر في الدم لدرجة خطیرة بمفرده. ورغم ذلك، لا تزال احتمالیة<br />حدوث نوبات ھبوط السكر في الدم مع استخدام زایتیرو قائمة.<br />. &bull; لا یُستخدم زایتیرو لمرضى السكري من النوع ۱<br />&bull; لا یُستخدم زایتیرو لمرضى الحماض السكري الكیتوني (زیادة الكیتونات في الدم أو البول).<br />من غیر المعلوم ما إذا كان استخدام زایتیرو آمنا وفعالا للأطفال تحت ۱۸ سنة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول زایتیرو :<br />.( &bull; إذا كنت مصاباً بالحساسیة للألوجلیبتین أو أي من المكونات الأخرى لھذا الدواء (المدرجة بالقسم ٦<br />&bull; إذا كنت قد أصبت برد فعل تحسسي خطیر لأي من العقاقیر الأخرى المماثلة التي تساعد في السیطرة على مستوى السكر<br />بدمك. وقد تشمل أعراض رد الفعل التحسسي الشدید: الطفح والبقع الحمراء البارزة على جلدك (الشرى) وتورم الوجھ<br />والشفاه واللسان والحلق الذین قد یسببون ضیق بالتنفس أو صعوبة بالبلع.<br />المحاذیر والاحتیاطات:<br />استشر طبیبك أو الصیدلي قبل تناول زایتیرو :<br />&bull; إذا كنت مصاباً بمرض السكري من النوع ۱ (لا ینتج جسدك الأنسولین).<br />&bull; إذا كنت مصاباً بالحماض الكیتوني السكري (وھو إحدى مضاعفات داء السكري التي تحدث عندما یعجز الجسم عن تكسیر<br />الجلوكوز بسبب عدم كفایة الأنسولین). وتشمل الأعراض العطش المفرط وكثرة التبول وفقدان الشھیة والغثیان أو القيء<br />وفقدان الوزن السریع.</p><p>&bull; إذا كنت تتناول دواء مضاد للسكري یسمى سالفونایل یوریا (مثل جلیبیزاید وتولبیوتاماید وجلیبینكلاماید) أو الأنسولین. قد<br />یرغب طبیبك في تخفیض جرعتك من السالفونایل یوریا أو الأنسولین عندما تتناول أیا منھما مع زایتیرو ، وذلك لتجنب<br />الانخفاض المفرط في مستوي السكر بالدم (نوبة ھبوط السكر بالدم).<br />&bull; إذا كنت تعاني من مرض كلوي، لا یزال بإمكانك تناول الدواء ولكن قد یقرر طبیبك تخفیض الجرعة.<br />&bull; إذا كنت تعاني من مرض كبدي.<br />&bull; إذا كنت تعاني من قصور قلبي.<br />&bull; إذا كنت قد أصبت برد فعل تحسسي لأي من العقاقیر الأخرى التي تساعد في السیطرة على مستوى السكر بدمك. وقد<br />تشمل الأعراض: الحكة العامة والإحساس بالحرارة، خصوصاً في فروة الرأس والفم والحلق وراحتي الكفین وأخمصي<br />القدمین (متلازمة ستیفن جونسون).<br />&bull; إذا كنت تتناول الأنسولین أو دواء مضاد للسكري، فقد یرغب طبیبك في تخفیض جرعتك من الأنسولین أو الدواء الآخر<br />المضاد للسكري عندما تتناول أیا منھما مع زایتیرو ، وذلك لتجنب انخفاض مستوى السكر بالدم.<br />&bull; إذا كنت مصابا بمرض في البنكریاس أو أصبت بھ من قبل.<br />الأطفال والمراھقین<br />لا یُوصى بزایتیرو للأطفال والمراھقین الأصغر سناً من ۱۸ عام بسبب انعدام البیانات في ھؤلاء المرضى.<br />العقاقیر الأخرى وزایتیرو<br />أخبر طبیبك أو الصیدلي إذا كنت تتعاطى أو تناولت مؤخر اً أو قد تتناول أیة عقاقیر أخرى.<br />الحمل والرضاعة<br />إذا كنتِ حامل أو ترضعین أو تعتقدي أنھ من الممكن أن تكوني حامل أو تخططین للحمل، فاطلبي المشورة من طبیبك أو الصیدلي<br />قبل تناول ھذا الدواء.<br />لا یوجد خبرة بصدد استخدام زایتیرو في النساء الحوامل أو خلال الرضاعة الطبیعیة. فلا یجب استخدام زایتیرو خلال الحمل أو<br />الرضاعة الطبیعیة، إلا إذا كان طبیبك یظن أنھ ضروري بشكل واضح.<br />القیادة واستخدام الآلات<br />لا یُعرف عن زایتیرو أنھ یؤثر على قدرتك على القیادة واستخدام الآلات. تناول زایتیرو في نفس الوقت مع دواء یسمى سالفونایل<br />یوریا أو الأنسولین أو كعلاج تولیفي مع ثیازولایدینیدیون زائد المیتفورمین یمكن أن یسبب انخفاض حاد في مستوى السكر بالدم<br />(نوبة انخفاض السكر بالدم)، ما قد یؤثر على قدرتك على القیادة واستخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; تناول زایتیرو بالطریقة التي أمرك بھا الطبیب بالضبط.<br />&bull; تناول زایتیرو مرة یومیا مع أو بدون الطعام.<br />&bull; إذا نسیت تناول جرعة تناولھا فور تذكرك. إن لم تتذكر حتى موعد الجرعة التالیة، تجاھل الجرعة التي نسیتھا وتناول<br />التي تلیھا في موعدھا الطبیعي. لا تتناول جرعتین من زایتیرو في نفس الوقت.<br />&bull; إذا تناولت الكثیر من زایتیرو (أكثر من الجرعة المقررة)، اتصل بطبیبك أو توجھ إلى غرفة الطوارئ في أقرب مستشفى<br />فورا.ً<br />&bull; إذا كان جسدك یعاني من الإجھاد نتیجة الحمى أو العدوى أو حادثة أو جراحة، فإن جرعة دواء السكري خاصتك قد تحتاج<br />لتعدیل. اتصل بطبیبك فورا.ً<br />&bull; حافظ على حمیتك الغذائیة وبرنامج تمارینك الریاضیة وافحص مستوى السكر في الدم حسب تعلیمات الطبیب.<br />&bull; قد یقوم طبیبك المعالج ببعض الفحوصات المعینة قبل أن تبدأ في استخدام زایتیرو وخلال العلاج حسب الحاجة. وقد یغیر<br />طبیبك من جرعة زایتیرو بناءً على نتائج فحوصات الدم التي أُجریت لك وفقاً لمدى جودة أداء كلیتیك لوظیفتیھما.<br />&bull; سیتابع طبیبك مرض السكري من خلال فحوصات الدم الدوریة، والتي تتضمن مستوي السكر في الدم واختبار الھیموجلوبین<br />Hemoglobin A1C<br />إذا تناولت جرعة زائدة عن المفترض من زایتیرو<br />إذا تناولت أقراص أكثر من الجرعة المفترضة، أو إذا تناول شخص آخر أو طفل دواءك، فاتصل أو توجھ إلى أقرب مركز طوارئ<br />فور ا.ً وخذ ھذه النشرة أو بعض الأقراص معك حتى یعرف طبیبك ماذا تناولت بالضبط.</p><p>إذا نسیت تناول زایتیرو<br />إذا فوَّت جرعة، تناولھا بمجرد تذكرھا. لا تتناول جرعة مضاعفة لتعویض الجرعة التي نسیتھا.<br />إذا توقفت عن تناول زایتیرو<br />لا تتوقف عن تناول زایتیرو بدون استشارة طبیبك أولا . فقد یرتفع مستوى السكر بدمك عندما تتوقف عن تناول زایتیرو .<br />إذا كان لدیك مزید من الأسئلة عن استخدام ھذا الدواء، اسأل طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جمیع العقاقیر، فإن ھذا الدواء قد یتسبب في حدوث آثار جانبیة، رغم أن ذلك لا یحدث في كل الحالات.<br />توقف عن تناول زایتیرو واتصل بالطبیب فور ا إًذا لاحظت أیا من الآثار الجانبیة الخطیرة التالیة:<br />غیر معروفة (لا یمكن تقییم التكرار من البیانات المتاحة):<br />&bull; رد فعل تحسسي. قد تشمل الأعراض: الطفح أو الشرى أو التورم أو مشاكل التنفس أو تورم الشفاه أو الوجھ أو الحلق أو<br />اللسان والشعور بالإغماء.<br />&bull; رد فعل تحسسي حاد: آفات الجلد أو البقع على جلدك والتي یمكن أن تتطور لتصیر قرحة محاطة بحلقات باھتة أو حمراء،<br />تكون البثور المتقرحة و/ أو تقشر الجلد وقد یصاحب ذلك أعراض مثل الحكة والحمى وشعور عام بالإعیاء وألم المفاصل<br />ومشاكل بالإبصار وشعور بالحرقان أو الألم أو الحكة بالعین وقرح الفم (متلازمة ستیفن جونز والحمامى متعددة الأشكال).<br />&bull; ألم حاد ومستمر في البطن (منطقة المعدة) والذي قد ینتشر إلى ظھرك، بالإضافة للغثیان والقيء والتي قد تكون علامة على<br />التھاب البنكریاس.<br />كما یجب أن تناقش طبیبك إذا شعرت بالآثار الجانبیة التالیة:<br />شائعة (قد تصیب حتى ۱ من كل ۱۰ أشخاص):<br />&bull; أعراض انخفاض مستوى السكر بالدم (نوبة ھبوط سكر الدم) قد تحدث عندما یتم تناول زایتیرو مع الأنسولین أو<br />السالفونایل یوریا (مثل جلیبیزاید وتولبیوتاماید وجلیبینكلاماید).<br />وقد تشمل الأعراض: الرعشة أو التعرق أو الاضطراب أو الزغللة أو خدر الشفاه أو الشحوب أو التغیرات المزاجیة أو<br />الشعور بالارتباك. وقد یھبط مستوى السكر بدمك تحت المستوى الطبیعي، ولكنھ یرتفع مجددا بتناول السكر. ویُوصى بأن<br />تحمل معك بضع مكعبات من السكر أو الحلوى أو البسكویت أو عصیر الفواكھ الغني بالسكر.<br />&bull; أعراض شبیھة بنزلات البرد مثل التھاب الحلق وانسداد الأنف<br />&bull; الطفح<br />&bull; حكة الجلد<br />&bull; الصداع.<br />&bull; مغص المعدة<br />&bull; الإسھال<br />&bull; عسر الھضم والحموضة</p><p>غیر معروفة<br />&bull; مشاكل الكبد مثل الغثیان أو القيء ، ألم المعدة ، إرھاق غیر عادي أو غیر مبرر، فقدان الشھیة ،اسمرار لون البول أو<br />اصفرار الجلد أو بیاض العینین.<br />الإبلاغ عن الآثار الجانبیة<br />إذا تعرضت لأي آثارٍ جانبیة أخبر طبیبك أو الصیدلي بما في ذلك أي آثارٍ جانبیةٍ محتملة لم تُذكر في ھذه النشرة. كما بإمكانك<br />الإبلاغ عن الآثار الجانبیة عن طریق المركز الوطني للتیقظ و السلامة الدوائیة المشار إلیھ في أسفل ھذه النشرة .یمكنك المساعدة<br />في توفیر المزید من المعلومات عن سلامة ھذا الدواء بالإبلاغ عن الآثار الجانبیة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یُخزن في درجة حرارة لا تزید عن ۳۰ درجة مئویة.<br />احتفظ بھذا الدواء بعیدا عن متناول ونظر الأطفال.</p><p>لا تستخدم ھذا الدواء بعد تاریخ انتھاء الصلاحیة المدون على العلبة و الشریط بعد كلمة (EXP) یشیر تاریخ انتھاء الصلاحیة إلى&nbsp;آخر یومٍ في الشھر المذكور.</p><p>لا تلقي أي أدویة في مصارف المیاه أو القمامة المنزلیة. اسأل الصیدلي عن طریقة التخلص من أي دواء لا تستخدمھ. ستساعد ھذه&nbsp;التدابیر في الحفاظ على البیئة. .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">ماذا یحتوي زایتیرو<br />- المادة الفعالة ھي ألوجلیبتین بنزوات.<br />یحتوي كل قرص ۱۲٫٥ ملجم على ألوجلیبتین بنزوات یعادل ۱۲٫٥ ملجم من الألوجلیبتین.<br />المكونات الأخرى ھي: مانیتول ومایكروكریستالین سیلیلوز، وھیدروكسي بروبیایل سیلیولوز، وكروسكارمیلوز الصودیوم، وسترات<br />الماغنیسیوم. بالإضافة إلى ذلك، فإن طبقة الغلاف تحتوي على المواد الخاملة التالیة: ھیبوبرومیلوز، وتیتانیوم دایوكسید، وأكسید<br />.F الحدید الأصفر (فریك أوكسید)، وبولي إیثلین جلیكول، والأقراص مُعلمة بحبر الطباعة الرمادي ۱<br />یحتوي كل قرص ۲٥ ملجم على ألوجلیبتین بنزوات یعادل ۲٥ ملجم من الألوجلیبتین.<br />المكونات الأخرى ھي: مانیتول ومایكروكریستالین سیلیلوز، وھیدروكسي بروبیایل سیلیولوز، وكروسكارمیلوز الصودیوم، وسترات<br />الماغنیسیوم. بالإضافة إلى ذلك، فإن طبقة الغلاف تحتوي على المواد الخاملة التالیة: ھیبوبرومیلوز، وتیتانیوم دایوكسید، وأكسید<br />. F1الحدید الأحمر (فریك أوكسید)، وبولي إیثلین جلیكول، والأقراص مُعلمة بحبر الطباعة الرمادي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>زایتیرو متوفر كأقراص مغلفة تحتوي على ۱۲٫٥ ملجم أو ۲٥ ملجم من ألوجلیبتین كما یلي:</p><p>زایتیرو ۱۲٫٥ ملجم أقراص مغلفة: صفراء، بیضاویة ومحدبة الجانبین، مطبوع على جانب واحد علامة&nbsp;&quot;TAK&quot;وعلامة&nbsp;.&#39;&#39;ALG-12.5&#39;&#39;</p><p>زایتیرو ۲٥ ملجم أقراص مغلفة: حمراء فاتحة، بیضاویة ومحدبة الجانبین، مطبوع على جانب واحد علامة&nbsp;&quot;TAK&quot;وعلامة&nbsp;&#39;ALG-25&#39;&#39;</p><p>یتوفر زایتیرو في عبوات تحتوي على ۲۸ قرصاً (العبوة تحتوي على ٤ شرائط یحتوي كل منھا على ۷ أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>:صاحب رخصة التسویق، موقع التعبئة والتغلیف الثانوي وموقع الإفراج النھائي<br />Batterjee pharmaceutical factory<br />Industrial Area-phase-IV,<br />Jeddah-21443, Kingdom of Saudi<br />المصنع:<br />Takeda Ireland Limited<br />Bray Business Park<br />Kilruddery, Bray<br />Co. Wicklow, Ireland<br />موقع التعبئة والتغلیف الأولي:<br />Packaging Coordinators, LLC<br />2200 Lake Shore Drive,<br />Woodstock, IL 60098, USA</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ینایر ۲۰۱٥
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zytero 25 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains alogliptin benzoate equivalent to 25 mg alogliptin. 
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet). 
Light red, oval, biconvex, film-coated tablet with “TAK” and “ALG-25” printed on one side

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.1.1 Monotherapy and Combination Therapy </strong></p><p>Zytero is indicated as an adjunct to diet and exercise to improve glycemic control in adults ( &ge; 18 years) with type 2 diabetes mellitus in multiple clinical settings.</p><p>&nbsp;</p><p><strong>4.1.2 Limitation of Use </strong></p><p>Zytero should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology </u></p><p><u>&nbsp;</u></p><p>For the different dose regimens, Zytero is available in strengths of 25 mg, 12.5 mg and 6.25 mg film-coated tablets.</p><p>&nbsp;</p><p><strong>Recommended Dosing </strong></p><p>The recommended dose of Zytero for adults ( &ge; 18 years) is 25 mg once daily. Zytero may be taken with or without food.</p><p>&nbsp;</p><p><strong>Special population:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Patients with Renal Impairment </strong></p><p>No dose adjustment of Zytero is necessary for patients with mild renal impairment (creatinine clearance [CrCl] &ge;60 mL/min).</p><p>&nbsp;</p><p>The dose of Zytero is 12.5 mg once daily for patients with moderate renal impairment (CrCl &ge;30 to &lt;60 mL/min).</p><p>&nbsp;</p><p>The dose of Zytero is 6.25 mg once daily for patients with severe renal impairment (CrCl &ge;15 toThe dose of Zytero is 6.25 mg once daily for patients with severe renal impairment</p><p>(CrCl &ge;15 to &lt;30 mL/min) or with end-stage renal disease (ESRD) (CrCl &lt;15 mL/min or</p><p>requiring hemodialysis). Zytero may be administered without regard to the timing of</p><p>dialysis. Zytero has not been studied in patients undergoing peritoneal dialysis.</p><p>&nbsp;</p><p>Because there is a need for dose adjustment based upon renal function, assessment of renal function is recommended prior to initiation of Zytero therapy and periodically thereafter.</p><p>&nbsp;</p><p><strong>Elderly Patients (&ge; 65 years old) </strong></p><p>No dose adjustment is necessary based on age. However, dosing of alogliptin should be conservative in patients with advanced age due to the potential for decreased renal function in this population.</p><p>&nbsp;</p><p><strong>Patients with Hepatic impairment </strong></p><p>No dose adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh scores of 5 to 9). Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9) and is, therefore, not recommended for use in such patients (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><strong>Paediatric population </strong></p><p>The safety and efficacy of Zytero in children and adolescents &lt; 18 years old have not been established. No data are available.</p><p><u>Method of administration</u></p><p>Oral use.</p><p>Zytero should be taken once daily with or without food. The tablets should be swallowed whole with water.</p><p>If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or history of a serious hypersensitivity reaction, including anaphylactic reaction, anaphylactic shock, and angioedema, to any dipeptidyl-peptidase-4 (DPP-4) inhibitor (see sections 4.4 and 4.8).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p><u>&nbsp;</u></p><p>Zytero should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Zytero is not a substitute for insulin in insulin-requiring patients.</p><p>&nbsp;</p><p><u>Use with other antihyperglycaemic medicinal products and hypoglycaemia</u></p><p><u>&nbsp;</u></p><p>Due to the increased risk of hypoglycaemia in combination with a sulphonylurea, insulin or combination therapy with thiazolidinedione plus metformin, a lower dose of these medications may be considered to reduce the risk of hypoglycaemia when these medicinal products are used in combination with alogliptin (see section 4.2).</p><p>&nbsp;</p><p><u>Combinations not studied</u></p><p><u>&nbsp;</u></p><p>Alogliptin has not been studied in combination with sodium glucose cotransporter 2 (SGLT-2) inhibitors or glucagon like peptide 1 (GLP-1) analogues nor formally as triple therapy with metformin and a sulphonylurea.</p><p>&nbsp;</p><p><u>Renal impairment </u></p><p>&nbsp;</p><p>As there is a need for dose adjustment in patients with moderate or severe renal impairment, or end-stage renal disease requiring dialysis, appropriate assessment of renal function is recommended prior to initiation of alogliptin therapy and periodically thereafter (see section 4.2).</p><p>&nbsp;</p><p>Experience in patients requiring renal dialysis is limited. Alogliptin has not been studied in patients undergoing peritoneal dialysis (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Hepatic impairment </u></p><p>&nbsp;</p><p>Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9) and is, therefore, not recommended for use in such patients (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>Cardiac failure </u></p><p>&nbsp;</p><p>Experience of alogliptin use in clinical trials in patients with congestive heart failure of New York Heart Association (NYHA) functional class III and IV is limited and caution is warranted in these patients.</p><p>&nbsp;</p><p><u>Hypersensitivity reactions </u></p><p><u>&nbsp;</u></p><p>Hypersensitivity reactions, including anaphylactic reactions, angioedema and exfoliative skin conditions including Stevens-Johnson syndrome and erythema multiforme have been observed for DPP-4 inhibitors and have been spontaneously reported for alogliptin in the post-marketing setting. In clinical studies of alogliptin, anaphylactic reactions were reported with a low incidence.</p><p>&nbsp;</p><p><u>Acute pancreatitis</u></p><p><u>&nbsp;</u></p><p>Use of DPP-4 inhibitors has been associated with a risk of developing acute pancreatitis. In a pooled analysis of the data from 13 studies, the overall rates of pancreatitis reports in patients treated with 25 mg alogliptin, 12.5 mg alogliptin, active control or placebo were 2, 1, 1 or 0 events per 1,000 patient years, respectively. In the cardiovascular outcomes study the rates of pancreatitis reports in patients treated with alogliptin or placebo were 3 or 2 events per 1,000 patient years, respectively. There have been spontaneously reported adverse reactions of acute pancreatitis in the post-marketing setting. Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain, which may radiate to the back. If pancreatitis is suspected, Zytero should be discontinued; if acute pancreatitis is confirmed, Zytero should not be restarted. Caution should be exercised in patients with a history of pancreatitis.</p><p>&nbsp;</p><p><u>Hepatic effects</u></p><p><u>&nbsp;</u></p><p>Postmarketing reports of hepatic dysfunction including hepatic failure have been received. A causal relationship has not been established. Patients should be observed closely for possible liver abnormalities. Obtain liver function tests promptly in patients with symptoms suggestive of liver injury. If an abnormality is found and an alternative etiology is not established, consider discontinuation of alogliptin treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of other medicinal products on alogliptin </u></p><p>&nbsp;</p><p>Alogliptin is primarily excreted unchanged in the urine and metabolism by the cytochrome (CYP) P450 enzyme system is negligible (see section 5.2). Interactions with CYP inhibitors are thus not expected and have not been shown.</p><p>&nbsp;</p><p>Results from clinical interaction studies also demonstrate that there are no clinically relevant effects of gemfibrozil (a CYP2C8/9 inhibitor), fluconazole (a CYP2C9 inhibitor), ketoconazole (a CYP3A4 inhibitor), cyclosporine (a p-glycoprotein inhibitor), voglibose (an alpha-glucosidase inhibitor), digoxin, metformin, cimetidine, pioglitazone or atorvastatin on the pharmacokinetics of alogliptin.</p><p>&nbsp;</p><p><u>Effects of alogliptin on other medicinal products</u></p><p><u>&nbsp;</u></p><p><em>In vitro</em> studies suggest that alogliptin does not inhibit nor induce CYP 450 isoforms at concentrations achieved with the recommended dose of 25 mg alogliptin (see section 5.2). Interaction with substrates of CYP 450 isoforms are thus not expected and have not been shown. In studies in vitro, alogliptin was found to be neither a substrate nor an inhibitor of key transporters associated with drug disposition in the kidney: organic anion transporter-1, organic anion transporter-3 or organic cationic transporter-2 (OCT2). Furthermore, clinical data do not suggest interaction with p-glycoprotein inhibitors or substrates.</p><p>&nbsp;</p><p>In clinical studies, alogliptin had no clinically relevant effect on the pharmacokinetics of caffeine, (R)-warfarin, pioglitazone, glyburide, tolbutamide, (S)-warfarin, dextromethorphan, atorvastatin, midazolam, an oral contraceptive (norethindrone and ethinyl oestradiol), digoxin, fexofenadine, metformin, or cimetidine, thus providing in vivo evidence of a low propensity to cause interaction with substrates of CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glycoprotein, and OCT2.</p><p>&nbsp;</p><p>In healthy subjects, alogliptin had no effect on prothrombin time or International Normalised Ratio (INR) when administered concomitantly with warfarin.</p><p>&nbsp;</p><p><u>Combination with other anti-diabetic medicinal products</u></p><p><u>&nbsp;</u></p><p>Results from studies with metformin, pioglitazone (thiazolidinedione), voglibose (alpha-glucosidase inhibitor) and glyburide (sulphonylurea) have shown no clinically relevant pharmacokinetic interactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy </u></p><p><strong>Pregnancy Category B</strong></p><p><strong>&nbsp;</strong></p><p>There are no data from the use of alogliptin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of alogliptin during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>It is unknown whether alogliptin is excreted in human milk. Animal studies have shown excretion of alogliptin in milk (see section 5.3). A risk to the suckling child cannot be excluded.</p><p>&nbsp;</p><p>A decision on whether to discontinue breast-feeding or to discontinue alogliptin therapy should be made taking into account the benefit of breast-feeding for the child and the benefit of alogliptin therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>The effect of alogliptin on fertility in humans has not been studied. No adverse effects on fertility were observed in animal studies (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zytero has no or negligible influence on the ability to drive and use machines. However patients should be alerted to the risk of hypoglycaemia especially when combined with a sulphonylurea, insulin or combination therapy with thiazolidinedione plus metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>The information provided is based on a total of 9,405 patients with type 2 diabetes mellitus, including 3,750 patients treated with 25 mg alogliptin and 2,476 patients treated with 12.5 mg alogliptin, who participated in one phase 2 or 12 phase 3 double-blind, placebo- or active-controlled clinical studies. In addition, a cardiovascular outcomes study with 5,380 patients with type 2 diabetes mellitus and a recent acute coronary syndrome event was conducted with 2,701 randomised to alogliptin and 2,679 randomised to placebo. These studies evaluated the effects of alogliptin on glycaemic control and its safety as monotherapy, as initial combination therapy with metformin or a thiazolidinedione, and as add-on therapy to metformin, or a sulphonylurea, or a thiazolidinedione (with or without metformin or a sulphonylurea), or insulin (with or without metformin).</p><p>&nbsp;</p><p>In a pooled analysis of the data from 13 studies, the overall incidences of adverse events, serious adverse events and adverse events resulting in discontinuation of therapy were comparable in patients treated with 25 mg alogliptin, 12.5 mg alogliptin, active control or placebo.</p><p>&nbsp;</p><p>The most common adverse reaction in patients treated with 25 mg alogliptin was headache.</p><p>&nbsp;</p><p>The safety of alogliptin between the elderly (&ge; 65 years old) and non-elderly (&lt; 65 years old) was similar.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>The adverse reactions are listed by system organ class and frequency. Frequencies are defined as very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from available data).</p><p>&nbsp;</p><p>In the pooled pivotal phase 3 controlled clinical trials of alogliptin as monotherapy and as add-on combination therapy involving 5,659 patients, the observed adverse reactions are listed below (Table 1).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 1: Adverse reactions observed in pooled pivotal phase 3 controlled clinical studies</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p><p>Adverse reaction</p></td><td style="vertical-align:top"><p><strong>Frequency of adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Infections and infestations</em></p><p>Upper respiratory tract infections</p><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Common</p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders</em></p><p>Headache</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p><p>Abdominal pain</p><p>Gastroesophageal reflux disease</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Common</p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p><p>Pruritus</p><p>Rash</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Common</p><p>Common</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Post-marketing experience</em></p><p>Table 2 shows additional adverse reactions which have been spontaneously reported post-marketing.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 2: Spontaneously reported alogliptin post-marketing adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p><p>Adverse reaction</p></td><td style="vertical-align:top"><p><strong>Frequency of adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders</em></p><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p><p>Acute pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorders</em></p><p>Hepatic dysfunction including hepatic failure</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p><p>Exfoliative skin conditions including</p><p>Stevens-Johnson syndrome</p><p>Erythema multiforme</p><p>Angioedema</p><p>Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p><p>Not known</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the <strong>National Pharmacovigilance and Drug Safety Centre (NPC)</strong> listed below:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull; Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222</p><p>Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&bull; Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The highest doses of alogliptin administered in clinical trials were single doses of 800 mg to healthy subjects and doses of 400 mg once daily for 14 days to patients with type 2 diabetes mellitus (equivalent to 32 times and 16 times the recommended daily dose of 25 mg alogliptin, respectively).</p><p>&nbsp;</p><p><u>Management</u></p><p>In the event of an overdose, appropriate supportive measures should be employed as dictated by the patient&rsquo;s clinical status.</p><p>&nbsp;</p><p>Minimal quantities of alogliptin are removed by haemodialysis (approximately 7% of the substance was removed during a 3-hour haemodialysis session). Therefore, haemodialysis is of little clinical benefit in overdose. It is not known if alogliptin is removed by peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes; dipeptidyl peptidase 4 (DPP-4) inhibitors.</p><p>&nbsp;</p><p>ATC code: A10BH04.</p><p>&nbsp;</p><p><u>Mechanism of action and pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p>Alogliptin is a potent and highly selective inhibitor of DPP-4, &gt;10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. DPP-4 is the principal enzyme involved in the rapid degradation of the incretin hormones, glucagon-like peptide-1 (GLP-1) and GIP (glucose-dependent insulinotropic polypeptide), which are released by the intestine and levels are increased in response to a meal. GLP-1 and GIP increases insulin biosynthesis and secretion from pancreatic beta cells, while GLP-1 also inhibits glucagon secretion and hepatic glucose production. Alogliptin therefore improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high.</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p><u>&nbsp;</u></p><p>Alogliptin has been studied as monotherapy, as initial combination therapy with metformin or a thiazolidinedione, and as add-on therapy to metformin, or a sulphonylurea, or a thiazolidinedione (with or without metformin or a sulphonylurea), or insulin (with or without metformin).</p><p>&nbsp;</p><p>Administration of 25 mg alogliptin to patients with type 2 diabetes mellitus produced peak inhibition of DPP-4 within 1 to 2 hours and exceeded 93% both after a single 25 mg dose and after 14 days of once-daily dosing. Inhibition of DPP-4 remained above 81% at 24 hours after 14 days of dosing. When the 4-hour postprandial glucose concentrations were averaged across breakfast, lunch and dinner, 14 days of treatment with 25 mg alogliptin resulted in a mean placebo-corrected reduction from baseline of -35.2 mg/dL.</p><p>&nbsp;</p><p>Both 25 mg alogliptin alone and in combination with 30 mg pioglitazone demonstrated significant decreases in postprandial glucose and postprandial glucagon whilst significantly increasing postprandial active GLP-1 levels at Week 16 compared to placebo (p &lt;0.05). In addition, 25 mg alogliptin alone and in combination with 30 mg pioglitazone produced statistically significant (p&lt;0.001) reductions in total triglycerides at Week 16 as measured by postprandial incremental AUC (0-8) change from baseline compared to placebo.</p><p>&nbsp;</p><p>A total of 14,779 patients with type 2 diabetes mellitus, including 6,448 patients treated with 25 mg alogliptin and 2,476 patients treated with 12.5 mg alogliptin, participated in one phase 2 or 13 phase 3 (including the cardiovascular outcomes study) double-blind, placebo- or active-controlled clinical studies conducted to evaluate the effects of alogliptin on glycaemic control and its safety. In these studies, 2,257 alogliptin-treated patients were &ge; 65 years old and 386 alogliptin-treated patients were &ge; 75 years old. The studies included 5,744 patients with mild renal impairment, 1,290 patients with moderate renal impairment and 82 patients with severe renal impairment / end-stage renal disease treated with alogliptin.</p><p>&nbsp;</p><p>Overall, treatment with the recommended daily dose of 25 mg alogliptin improved glycaemic control when given as monotherapy and as initial or add-on combination therapy. This was determined by clinically relevant and statistically significant reductions in glycosylated haemoglobin (HbA1c) and fasting plasma glucose compared to control from baseline to study endpoint. Reductions in HbA1c were similar across different subgroups including renal impairment, age, gender and body mass index, while differences between races (e.g. White and non-White) were small. Clinically meaningful reductions in HbA1c compared to control were also observed with 25 mg alogliptin regardless of baseline background treatment. Higher baseline HbA1c was associated with a greater reduction in HbA1c. Generally, the effects of alogliptin on body weight and lipids were neutral.</p><p>&nbsp;</p><p><em>Alogliptin as monotherapy </em></p><p>Treatment with 25 mg alogliptin once daily resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose compared to placebo-control at Week 26 (Table 3).</p><p>&nbsp;</p><p><em>Alogliptin as add-on therapy to metformin </em></p><p>The addition of 25 mg alogliptin once daily to metformin hydrochloride therapy (mean dose = 1,847 mg) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 3). Significantly more patients receiving 25 mg alogliptin (44.4%) achieved target HbA1c levels of &le; 7.0% compared to those receiving placebo (18.3%) at Week 26 (p &lt;0.001).</p><p>&nbsp;</p><p>The addition of 25 mg alogliptin once daily to metformin hydrochloride therapy (mean dose = 1,835 mg) resulted in improvements from baseline in HbA1c at Week 52 and Week 104. At Week 52, the HbA1c reduction by 25 mg alogliptin plus metformin (-0.76%, Table 4) was similar to that produced by glipizide (mean dose = 5.2 mg) plus metformin hydrochloride therapy (mean dose = 1,824 mg, -0.73%). At Week 104, the HbA1c reduction by 25 mg alogliptin plus metformin (- 0.72%, Table 4) was greater than that produced by glipizide plus metformin (-0.59%). Mean change from baseline in fasting plasma glucose at Week 52 for 25 mg alogliptin and metformin was significantly greater than that for glipizide and metformin (p &lt;0.001). By Week 104, mean change from baseline in fasting plasma glucose for 25 mg alogliptin and metformin was -3.2 mg/dL compared with 5.4 mg/dL for glipizide and metformin. More patients receiving 25 mg alogliptin and metformin (48.5%) achieved target HbA1c levels of &le; 7.0% compared to those receiving glipizide and metformin (42.8%) (p=0.004).</p><p>&nbsp;</p><p><em>Alogliptin as add-on therapy to a sulphonylurea </em></p><p>The addition of 25 mg alogliptin once daily to glyburide therapy (mean dose = 12.2 mg) resulted in statistically significant improvements from baseline in HbA1c at Week 26 when compared to the addition of placebo (Table 3). Mean change from baseline in fasting plasma glucose at Week 26 for 25 mg alogliptin showed a reduction of 8.4 mg/dL compared to an increase of 2.2 mg/dL with placebo. Significantly more patients receiving 25 mg alogliptin (34.8%) achieved target HbA1c levels of &le; 7.0% compared to those receiving placebo (18.2%) at Week 26 (p=0.002).</p><p>&nbsp;</p><p><em>Alogliptin as add-on therapy to a thiazolidinedione </em></p><p>The addition of 25 mg alogliptin once daily to pioglitazone therapy (mean dose = 35.0 mg, with or without metformin or a sulphonylurea) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 3). Clinically meaningful reductions in HbA1c compared to placebo were also observed with 25 mg alogliptin regardless of whether patients were receiving concomitant metformin or sulphonylurea therapy. Significantly more patients receiving 25 mg alogliptin (49.2%) achieved target HbA1c levels of &le; 7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004).</p><p>&nbsp;</p><p><em>Alogliptin as add-on therapy to a thiazolidinedione with metformin </em></p><p>The addition of 25 mg alogliptin once daily to 30 mg pioglitazone and metformin hydrochloride therapy (mean dose = 1,867.9 mg) resulted in improvements from baseline in HbA1c at Week 52 that were both non-inferior and statistically superior to those produced by 45 mg pioglitazone and metformin hydrochloride therapy (mean dose = 1,847.6 mg, Table 4). The significant reductions in HbA1c observed with 25 mg alogliptin plus 30 mg pioglitazone and metformin were consistent over the entire 52-week treatment period compared to 45 mg pioglitazone and metformin (p&lt;0.001).</p><p>&nbsp;</p><p><em>Alogliptin as add-on therapy to insulin (with or without metformin) </em></p><p>The addition of 25 mg alogliptin once daily to insulin therapy (mean dose = 56.5 IU, with or without metformin) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 3). Clinically meaningful reductions in HbA1c compared to placebo were also observed with 25 mg alogliptin regardless of whether patients were receiving concomitant metformin therapy. More patients receiving 25 mg alogliptin (7.8%) achieved target HbA1c levels of &le; 7.0% compared to those receiving placebo (0.8%) at Week 26.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 3: Change in HbA1c (%) from baseline with alogliptin 25 mg at Week 26 by placebo-controlled study (FAS, LOCF)</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td style="vertical-align:top"><p><strong>Mean baseline HbA1c (%) (SD</strong></p></td><td style="vertical-align:top"><p><strong>Mean change from baseline in HbA1c (%)&dagger; (SE)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo-corrected change from baseline in HbA1c (%)&dagger; (2-sided 95% CI)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Monotherapy placebo-controlled study</em></p></td></tr><tr><td style="vertical-align:top"><p>Alogliptin 25 mg once daily</p><p>(n=128)</p></td><td style="vertical-align:top"><p>7.91</p><p>(0.788)</p></td><td style="vertical-align:top"><p>-0.59</p><p>(0.066)</p></td><td style="vertical-align:top"><p>-0.57*</p><p>(-0.80, -0.35)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Add-on combination therapy placebo-controlled studies</em></p></td></tr><tr><td style="vertical-align:top"><p>Alogliptin 25 mg once daily with metformin</p><p>(n=203)</p></td><td style="vertical-align:top"><p>7.93</p><p>(0.799)</p></td><td style="vertical-align:top"><p>-0.59</p><p>(0.054)</p></td><td style="vertical-align:top"><p>-0.48*</p><p>(-0.67, -0.30)</p></td></tr><tr><td style="vertical-align:top"><p>Alogliptin 25 mg once daily with a sulphonylurea (n=197)</p></td><td style="vertical-align:top"><p>8.09</p><p>(0.898)</p></td><td style="vertical-align:top"><p>-0.52</p><p>(0.058)</p></td><td style="vertical-align:top"><p>-0.53*</p><p>(-0.73, -0.33)</p></td></tr><tr><td style="vertical-align:top"><p>Alogliptin 25 mg once daily with a thiazolidinedione &plusmn; metformin or a sulphonylurea (n=195)</p></td><td style="vertical-align:top"><p>8.01</p><p>(0.837)</p></td><td style="vertical-align:top"><p>-0.80</p><p>(0.056)</p></td><td style="vertical-align:top"><p>-0.61*</p><p>(-0.80, -0.41)</p></td></tr><tr><td style="vertical-align:top"><p>Alogliptin 25 mg once daily with insulin + metformin (n=126)</p></td><td style="vertical-align:top"><p>9.27</p><p>(1.127)</p></td><td style="vertical-align:top"><p>-0.71</p><p>(0.078)</p></td><td style="vertical-align:top"><p>-0.59*</p><p>(-0.80, -0.37)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>FAS = full analysis set</p><p>LOCF = last observation carried forward</p><p>&dagger; Least squares means adjusted for prior antihyperglycaemic therapy status and baseline values</p><p>* p&lt;0.001 compared to placebo or placebo+combination treatment</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 4: Change in HbA1c (%) from baseline with alogliptin 25 mg by active-controlled study (PPS, LOCF)</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Study</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Mean baseline HbA1c (%) (SD)</strong></p></td><td style="vertical-align:top"><p><strong>Mean change from baseline in HbA1c (%)&dagger; (SE)</strong></p></td><td style="vertical-align:top"><p><strong>Treatment-corrected change from baseline in HbA1c (%)&dagger; (1-sided CI)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Add-on combination therapy studies</em></p></td></tr><tr><td style="vertical-align:top"><p>Alogliptin 25 mg once daily with metformin vs a sulphonylurea + metformin</p><p>&nbsp;</p><p>Change at Week 52 (n=382)</p><p>&nbsp;</p><p>&nbsp;</p><p>Change at Week 104 (n=382)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>7.61</p><p>(0.526)</p><p>&nbsp;</p><p>&nbsp;</p><p>7.61</p><p>(0.526)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>-0.76</p><p>(0.027)</p><p>&nbsp;</p><p>&nbsp;</p><p>-0.72</p><p>(0.037)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>-0.03</p><p>(-infinity, 0.059)</p><p>&nbsp;</p><p>&nbsp;</p><p>-0.13*</p><p>(-infinity, -0.006)</p></td></tr><tr><td style="vertical-align:top"><p>Alogliptin 25 mg once daily with a thiazolidinedione + metformin vs a titrating thiazolidinedione + metformin</p><p>&nbsp;</p><p>Change at Week 26 (n=303)</p><p>&nbsp;</p><p>Change at Week 52 (n=303)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>8.25 (0.820)</p><p>&nbsp;</p><p>8.25 (0.820)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>-0.89 (0.042)</p><p>&nbsp;</p><p>-0.70 (0.048)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>-0.47* (-infinity, -0.35)</p><p>&nbsp;</p><p>-0.42* (-infinity, -0.28)</p><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>PPS = per protocol set</p><p>LOCF = last observation carried forward</p><p>* Non inferiority and superiority statistically demonstrated</p><p>&dagger; Least squares means adjusted for prior antihyperglycaemic therapy status and baseline values</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><em>Patients with renal impairment </em></p><p>The efficacy and safety of the recommended doses of alogliptin were investigated separately in a subgroup of patients with type 2 diabetes mellitus and severe renal impairment/end-stage renal disease in a placebo-controlled study (59 patients on alogliptin and 56 patients on placebo for 6 months) and found to be consistent with the profile obtained in patients with normal renal function.</p><p>&nbsp;</p><p><em>Elderly (&ge; 65 years old) </em></p><p>The efficacy of alogliptin in patients with type 2 diabetes mellitus and &ge; 65 years old across a pooled analysis of five 26-week placebo-controlled studies was consistent with that in patients &lt; 65 years old.</p><p>&nbsp;</p><p>In addition, treatment with 25 mg alogliptin once daily resulted in improvements from baseline in HbA1c at Week 52 that were similar to those produced by glipizide (mean dose = 5.4 mg). Importantly, despite alogliptin and glipizide having similar HbA1c and fasting plasma glucose changes from baseline, episodes of hypoglycaemia were notably less frequent in patients receiving 25 mg alogliptin (5.4%) compared to those receiving glipizide (26.0%).</p><p>&nbsp;</p><p><u>Clinical safety</u></p><p><u>&nbsp;</u></p><p><em>Cardiovascular Safety </em></p><p>In a pooled analysis of the data from 13 studies, the overall incidences of cardiovascular death, non fatal myocardial infarction and non-fatal stroke were comparable in patients treated with 25 mg alogliptin, active control or placebo.</p><p>&nbsp;</p><p>In addition, a prospective randomized cardiovascular outcomes safety study was conducted with 5,380 patients with high underlying cardiovascular risk to examine the effect of alogliptin compared with placebo (when added to standard of care) on major adverse cardiovascular events (MACE) including time to the first occurrence of any event in the composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke in patients with a recent (15 to 90 days) acute coronary event. At baseline, patients had a mean age of 61 years, mean duration of diabetes of 9.2 years, and mean HbA1c of 8.0%.</p><p>&nbsp;</p><p>The study demonstrated that alogliptin did not increase the risk of having a MACE compared to placebo [Hazard Ratio: 0.96; 1-sided 99% Confidence Interval: 0-1.16]. In the alogliptin group, 11.3% of patients experienced a MACE compared to 11.8% of patients in the placebo group.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 5. MACE Reported in cardiovascular outcomes study</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Number of Patients (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Alogliptin 25 mg</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p>N=2,701</p></td><td style="vertical-align:top"><p>N=2,679</p></td></tr><tr><td style="vertical-align:top"><p><strong>Primary Composite Endpoint [First Event of CV Death, Nonfatal MI and Nonfatal Stroke]</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>305 (11.3)</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>316 (11.8)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular Death*</p></td><td style="vertical-align:top"><p>89 (3.3)</p></td><td style="vertical-align:top"><p>111 (4.1)</p></td></tr><tr><td style="vertical-align:top"><p>Nonfatal Myocardial Infarction</p></td><td style="vertical-align:top"><p>187 (6.9)</p></td><td style="vertical-align:top"><p>173 (6.5)</p></td></tr><tr><td style="vertical-align:top"><p>Nonfatal Stroke</p></td><td style="vertical-align:top"><p>29 (1.1)</p></td><td style="vertical-align:top"><p>32 (1.2)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Overall there were 153 subjects (5.7%) in the alogliptin group and 173 subjects (6.5%) in the placebo group who died (all-cause mortality).</p><p>&nbsp;</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>There were 703 patients who experienced an event within the secondary MACE composite endpoint (first event of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke and urgent revascularization due to unstable angina). In the alogliptin group, 12.7% (344 subjects) experienced an event within the secondary MACE composite endpoint, compared with 13.4% (359 subjects) in the placebo group [Hazard Ratio = 0.95; 1-sided 99% Confidence Interval: 0-1.14].</p><p>&nbsp;</p><p><em>Hypoglycaemia </em></p><p>In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was lower in patients treated with 25 mg alogliptin than in patients treated with 12.5 mg alogliptin, active control or placebo (3.6%, 4.6%, 12.9% and 6.2%, respectively). The majority of these episodes were mild to moderate in intensity. The overall incidence of episodes of severe hypoglycaemia was comparable in patients treated with 25 mg alogliptin or 12.5 mg alogliptin, and lower than the incidence in patients treated with active control or placebo (0.1%, 0.1%, 0.4% and 0.4%, respectively). In the prospective randomized controlled cardiovascular outcomes study, investigator reported events of hypoglycemia were similar in patients receiving placebo (6.5%) and patients receiving alogliptin (6.7%) in addition to standard of care.</p><p>&nbsp;</p><p>In a clinical trial of alogliptin as mono-therapy, the incidence of hypoglycaemia was similar to that of placebo, and lower than placebo in another trial as add-on to a sulphonylurea.</p><p>&nbsp;</p><p>Higher rates of hypoglycaemia were observed with triple therapy with thiazolidinedione and metformin and in combination with insulin, as observed with other DPP-4 inhibitors.</p><p>&nbsp;</p><p>Patients (&ge; 65 years old) with type 2 diabetes mellitus are considered more susceptible to episodes of hypoglycaemia than patients &lt; 65 years old. In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was similar in patients &ge; 65 years old treated with 25 mg alogliptin (3.8%) to that in patients &lt; 65 years old (3.6%).</p><p>&nbsp;</p><p><u>Paediatric population </u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Zytero in one or more subsets of the paediatric population in the treatment of type 2 diabetes mellitus (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of alogliptin has been shown to be similar in healthy subjects and in patients with type 2 diabetes mellitus.</p><p>&nbsp;</p><p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>The absolute bioavailability of alogliptin is approximately 100%.</p><p>&nbsp;</p><p>Administration with a high-fat meal resulted in no change in total and peak exposure to alogliptin. Zytero may, therefore, be administered with or without food.</p><p>&nbsp;</p><p>After administration of single, oral doses of up to 800 mg in healthy subjects, alogliptin was rapidly absorbed with peak plasma concentrations occurring 1 to 2 hours (median Tmax) after dosing.</p><p>&nbsp;</p><p>No clinically relevant accumulation after multiple dosing was observed in either healthy subjects or in patients with type 2 diabetes mellitus.</p><p>&nbsp;</p><p>Total and peak exposure to alogliptin increased proportionately across single doses of 6.25 mg up to 100 mg alogliptin (covering the therapeutic dose range). The inter-subject coefficient of variation for alogliptin AUC was small (17%).</p><p>&nbsp;</p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>Following a single intravenous dose of 12.5 mg alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L indicating that the drug is well distributed into tissues.</p><p>&nbsp;</p><p>Alogliptin is 20-30% bound to plasma proteins.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>Alogliptin does not undergo extensive metabolism, 60-70% of the dose is excreted as unchanged drug in the urine.</p><p>&nbsp;</p><p>Two minor metabolites were detected following administration of an oral dose of [14C] alogliptin, N-demethylated alogliptin, M-I (&lt; 1% of the parent compound), and N-acetylated alogliptin, M-II (&lt; 6% of the parent compound). M-I is an active metabolite and is a highly selective inhibitor of DPP-4 similar to alogliptin; M-II does not display any inhibitory activity towards DPP-4 or other DPP-related enzymes. In vitro data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.</p><p>&nbsp;</p><p><em>In vitro</em> studies indicate that alogliptin does not induce CYP1A2, CYP2B6 and CYP2C9 and does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 at concentrations achieved with the recommended dose of 25 mg alogliptin. Studies in vitro have shown alogliptin to be a mild inducer of CYP3A4, but alogliptin has not been shown to induce CYP3A4 in studies in vivo.</p><p>&nbsp;</p><p>In studies in vitro, alogliptin was not an inhibitor of the following renal transporters; OAT1, OAT3 and OCT2.</p><p>&nbsp;</p><p>Alogliptin exists predominantly as the (R)-enantiomer (&gt; 99%) and undergoes little or no chiral conversion in vivo to the (S)-enantiomer. The (S)-enantiomer is not detectable at therapeutic doses.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>Alogliptin was eliminated with a mean terminal half-life (T1/2) of approximately 21 hours.</p><p>&nbsp;</p><p>Following administration of an oral dose of [14C] alogliptin, 76% of total radioactivity was eliminated in the urine and 13% was recovered in the faeces.</p><p>&nbsp;</p><p>The average renal clearance of alogliptin (170 mL/min) was greater than the average estimated glomerular filtration rate (approx. 120 mL/min), suggesting some active renal excretion.</p><p>&nbsp;</p><p><u>Time-dependency</u></p><p>Total exposure (AUC(0-inf)) to alogliptin following administration of a single dose was similar to exposure during one dose interval (AUC(0-24)) after 6 days of once daily dosing. This indicates no time-dependency in the kinetics of alogliptin after multiple dosing.</p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>Renal impairment </em></p><p>A single-dose of 50 mg alogliptin was administered to 4 groups of patients with varying degrees of renal impairment (creatinine clearance (CrCl) using the Cockcroft-Gault formula): mild (CrCl = &gt; 50 to &le; 80 mL/min), moderate (CrCl = &ge; 30 to &le; 50 mL/min), severe (CrCl = &lt; 30 mL/min) and end-stage renal disease on haemodialysis.</p><p>&nbsp;</p><p>An approximate 1.7-fold increase in AUC for alogliptin was observed in patients with mild renal impairment. However, as the distribution of AUC values for alogliptin in these patients was within the same range as control subjects, no dose adjustment for patients with mild renal impairment is necessary (see section 4.2).</p><p>&nbsp;</p><p>In patients with moderate or severe renal impairment, or end-stage renal disease on haemodialysis, an increase in systemic exposure to alogliptin of approximately 2- and 4-fold was observed, respectively. (Patients with end-stage renal disease underwent haemodialysis immediately after alogliptin dosing. Based on mean dialysate concentrations, approximately 7% of the drug was removed during a 3-hour haemodialysis session.) Therefore, in order to maintain systemic exposures to alogliptin that are similar to those observed in patients with normal renal function, lower doses of alogliptin should be used in patients with moderate or severe renal impairment, or end-stage renal disease requiring dialysis (see section 4.2).</p><p>&nbsp;</p><p><em>Hepatic impairment </em></p><p>Total exposure to alogliptin was approximately 10% lower and peak exposure was approximately 8% lower in patients with moderate hepatic impairment compared to healthy control subjects. The magnitude of these reductions was not considered to be clinically relevant. Therefore, no dose adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh scores of 5 to 9). Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9, see section 4.2).</p><p>&nbsp;</p><p><em>Age, gender, race, body weight </em></p><p>Age (65-81 years old), gender, race (white, black and Asian) and body weight did not have any clinically relevant effect on the pharmacokinetics of alogliptin. No dose adjustment is necessary (see section 4.2).</p><p>&nbsp;</p><p><em>Paediatric population </em></p><p>The pharmacokinetics of alogliptin in children and adolescents &lt; 18 years old has not been established. No data are available (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and toxicology.</p><p>&nbsp;</p><p>The no-observed-adverse-effect level (NOAEL) in the repeated dose toxicity studies in rats and dogs up to 26 and 39 weeks in duration, respectively, produced exposure margins that were approximately 147- and 227-fold, respectively, the exposure in humans at the recommended dose of 25 mg alogliptin.</p><p>&nbsp;</p><p>Alogliptin was not genotoxic in a standard battery of in vitro and in vivo genotoxicity studies.</p><p>&nbsp;</p><p>Alogliptin was not carcinogenic in 2-year carcinogenicity studies conducted in rats and mice. Minimal to mild simple transitional cell hyperplasia was seen in the urinary bladder of male rats at the lowest dose used (27 times the human exposure) without establishment of a clear NOEL (no observed effect level).</p><p>&nbsp;</p><p>No adverse effects of alogliptin were observed upon fertility, reproductive performance, or early embryonic development in rats up to a systemic exposure far above the human exposure at the recommended dose. Although fertility was not affected, a slight, statistical increase in the number of abnormal sperm was observed in males at an exposure far above the human exposure at the recommended dose.</p><p>&nbsp;</p><p>Placental transfer of alogliptin occurs in rats.</p><p>&nbsp;</p><p>Alogliptin was not teratogenic in rats or rabbits with a systemic exposure at the NOAELs far above the human exposure at the recommended dose. Higher doses of alogliptin were not teratogenic but resulted in maternal toxicity, and were associated with delayed and/or lack of ossification of bones and decreased foetal body weights.</p><p>&nbsp;</p><p>In a pre- and postnatal development study in rats, exposures far above the human exposure at the recommended dose did not harm the developing embryo or affect offspring growth and development. Higher doses of alogliptin decreased offspring body weight and exerted some developmental effects considered secondary to the low body weight.</p><p>&nbsp;</p><p>Studies in lactating rats indicate that alogliptin is excreted in milk.</p><p>&nbsp;</p><p>No alogliptin-related effects were observed in juvenile rats following repeat-dose administration for 4 and 8 weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Microcrystalline cellulose</p><p>Hydroxypropyl cellulose</p><p>Croscarmellose sodium</p><p>Magnesium stearate</p><p>In addition, the film-coating contains the following inactive ingredients: hypromellose, titanium dioxide, ferric oxide (Red) and polyethylene glycol and is marked with gray F1 printing ink.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Primary Packaging Material:</strong> The packaging configuration for blister packs is constructed of aluminum forming material and aluminum lidding material.</p><p><strong>Secondary Packaging Material:</strong> Carton.</p><p>Pack sizes of 10, 14, 28, 30, 56, 60, 84, 90, 98 or 100 film-coated tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Batterjee pharmaceutical factory
Industrial Area-phase-IV,
Jeddah-21443, Kingdom of Saudi
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>